Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cardinal Health Inc Market Cap
Based on ratings from 16 stock analysts, the Cardinal Health Inc stock price is expected to increase by 7.19% in 12 months. This is calculated by using the average 12-month stock price forecast for Cardinal Health Inc. The lowest target is $101 and the highest is $140. Please note analyst price targets are not guaranteed and could be missed completely.
About 16 Wall Street analysts have assigned CAH 1 buy ratings, 15 hold ratings, and 0 sell ratings. This means that analysts expect Cardinal Health Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CAH. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CAH.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Toung Argus Research | Buy | $125 | Maintains | Sep 11, 2024 |
| Lisa Gill JP Morgan | Neutral | $123 | Maintains | Aug 21, 2024 |
| George Hill Deutsche Bank | Hold | $119 | Maintains | Aug 16, 2024 |
| Kevin Caliendo UBS | Buy | $125 | Maintains | Aug 15, 2024 |
| Erin Wright Morgan Stanley | Overweight | $119 | Maintains | Aug 15, 2024 |
| Stephen Baxter Wells Fargo | Underweight | $101 | Maintains | Aug 15, 2024 |
| Eric Coldwell Baird | Outperform | $137 | Maintains | Aug 15, 2024 |
| Elizabeth Anderson Evercore ISI Group | In-Line | $115 | Maintains | Aug 15, 2024 |
| Daniel Grosslight Citigroup | Neutral | $107 | Maintains | Jul 19, 2024 |
| Elizabeth Anderson Evercore ISI Group | In-Line | $105 | Maintains | Jul 9, 2024 |
| Eric Coldwell Baird | Outperform | $130 | Maintains | Jul 9, 2024 |
| David Toung Argus Research | Buy | $115 | Maintains | May 15, 2024 |
Deutsche Bank | Hold | Maintains | May 6, 2024 | |
| Elizabeth Anderson Evercore ISI Group | In-Line | $115 | Maintains | May 3, 2024 |
| Eric Coldwell Baird | Outperform | $128 | Maintains | May 3, 2024 |
| Stephen Baxter Wells Fargo | Underweight | $94 | Maintains | Apr 29, 2024 |
| Michael Cherny Leerink Partners | Outperform | $125 | Initiates | Feb 26, 2024 |
| David Toung Argus Research | Buy | Upgrade | Feb 9, 2024 | |
| Kevin Caliendo UBS | Buy | $125 | Maintains | Feb 5, 2024 |
| Kevin Caliendo UBS | Buy | $122 | Maintains | Jan 29, 2024 |
When did it IPO
1987
Staff Count
47,922
Country
United States
Sector/Industry
Healthcare/Medical Distribution
CEO
Mr. Jason M. Hollar
Market Cap
$26.70B
In 2023, CAH generated $204.98B in revenue, which was a increase of 13.04% from the previous year. This can be seen as a signal that CAH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 01 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Premium offers Style Scores to help investors identify strong stocks across value, growth, and momentum categories.
Why It Matters - Zacks Style Scores enhance stock selection for various investment strategies, potentially improving portfolio performance and risk management for investors.
Tue, 24 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Cardinal Health (NYSE: CAH) will release its Q1 financial results for fiscal year 2025 on November 1, before NYSE trading opens.
Why It Matters - Cardinal Health's upcoming financial results release could impact stock performance and market sentiment, influencing investment decisions and valuations in the healthcare sector.
Tue, 24 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Cardinal Health (CAH) will acquire Oncology Network for $1.115 billion, enhancing its oncology services and community cancer care across 10 states.
Why It Matters - CAH's $1.115 billion acquisition of Oncology Network enhances its market presence in oncology, potentially increasing revenue and improving competitive positioning in cancer care.
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks emphasizes its Zacks Rank system, which uses earnings estimates and revisions to identify strong stocks, while also monitoring value, growth, and momentum trends.
Why It Matters - The Zacks Rank system highlights earnings estimates and revisions, offering insights into stock potential. Value, growth, and momentum trends indicate strong investment opportunities.
Fri, 20 Sep 2024
Sentiment - POSITIVE
Source - Reuters
Summary - Cardinal Health has announced the acquisition of Integrated Oncology Network for $1.12 billion in cash, expanding its presence in the oncology sector.
Why It Matters - The acquisition enhances Cardinal Health's position in the oncology market, potentially increasing revenue streams and market share, which could positively impact stock performance.
Fri, 20 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Cardinal Health will acquire Integrated Oncology Network for $1.115B, enhancing its investment in specialty and oncology care with over 100 providers across 10 states.
Why It Matters - Cardinal Health's acquisition of Integrated Oncology Network enhances its oncology capabilities, expands market reach, and signals growth potential, which can positively impact its stock value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
